- Have recently been diagnosed with AL (light chain) amyloidosis affecting the heart;
- And you have not yet begun treatment for your amyloidosis,
- You may be eligible for a clinical trial for the investigational agent, CAEL-101
Caelum Biosciences has two ongoing Phase 3 clinical trials study to determine if CAEL-101 has a benefit in patients with severe Cardiac AL Light Chain Amyloidosis.
Copyright 2020. Caelum Biosciences